I believe this stock has the potential to grow naturally without RMAT, upon positive quarterly's for the rest of the year. If we show positive growth and profits, the PPS should rise accordingly. As long as we're getting the customers needed to bring in revenue and business is profitable, we're good. USRM will continue US operations unless a "cease and desist" is ordered by the govt., in which, they will just continue operations overseas and continue to bring in revenue. If RMAT is approved, we have official govt. assurance, which will demand a response by big-pharma and bring confidence from big money.